30 March 2006
For Immediate Release
Hypoguard USA
Hypoguard Receives 510(k) Clearance To Market Assure® Pro Blood Glucose Monitoring System
-New full-featured blood glucose system designed specifically for Long-Term Care-
Minneapolis, MN, March 30, 2006 - Hypoguard announced today it has received 510(k)
clearance from the U.S. Food and Drug Administration (FDA) to market its Assure® Pro Blood
Glucose Monitoring System.
Assure® Pro is specifically designed for multi-resident use in long-term care (LTC) facilities. This
full-featured system offers qcProGuard™, the first of its kind, 24-hour reminder to conduct daily
control solution testing as required in LTC settings. A "Hypo" warning alerts users of low blood
glucose readings and four programmable alarms can be used as test reminders. Assure Pro
Test Strips are built using platinum technology and require a small blood sample size (1 _L). To
test, simply insert the test strip in the convenient top-of-the-meter port. Results are displayed in
10 seconds on a large LCD and a backlight display (adjustable) assists for reading in low light
conditions. A strip release button for strip disposal eliminates the need to touch a used strip,
reducing the risk of exposure to infectious materials. For additional security, Assure Pro is
designed with ProGrip™ to help secure a hold on the meter and reduce slipping on surfaces.
"Our expertise has always been in LTC and we are very excited to launch the Assure Pro
System into our core market," said Dave Conn, President of Hypoguard USA. "Many of the
features in this system were designed based on feedback from healthcare professionals. This
innovative, easy-to-use, and full-featured blood glucose system meets the diverse needs of
healthcare workers. We expect this to become the premier product in LTC."
The Assure Pro Blood Glucose Monitoring System will be available in April 2006.
About Hypoguard USA
Hypoguard (www.hypoguard.com) is a leading healthcare company specializing in diagnostic
products and medical devices at the point of care. Hypoguard develops, manufactures and
markets innovative diagnostic products and related medical devices used in managing chronic
diseases such as diabetes, screening for acute conditions utilizing blood and urine diagnostics,
and enhancing healthcare worker safety. The company's primary products include a broad line
of blood glucose monitoring systems, safety lancets and lancing devices, as well as urine
testing equipment and supplies. Hypoguard's focus is to improve today's technology to develop
products that are even more convenient and safe.
- Ends -
Contact:
Hypoguard USA
Dave Conn, President
Michelle Dumonceaux, Senior Marketing Manager
952.646.3201
952.646.3225
info@hypoguard.com
[Download PDF]
